PHASE-II TRIAL OF WHOLE-CELL PERTUSSIS-VACCINE VS AN ACELLULAR VACCINE CONTAINING AGGLUTINOGENS

被引：42

作者：

MILLER, E ^{[1
]}

ASHWORTH, LAE ^{[1
]}

ROBINSON, A ^{[1
]}

WAIGHT, PA ^{[1
]}

IRONS, LI ^{[1
]}

机构：

[1] PUBL HLTH LAB SERV,SALISBURY,ENGLAND

来源：

LANCET | 1991年 / 337卷 / 8733期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1016/0140-6736(91)90735-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An acellular pertussis vaccine containing agglutinogens 2 and 3, pertussis toxin, and filamentous haemagglutinin was developed by the Centre for Applied Microbiology and Research in the UK. 188 infants were entered into a randomised blind trial and received either the acellular or a whole-cell vaccine, combined with diphtheria and tetanus toxoids, in a 3, 5, and 8-10 month schedule. Local reactions were similar in the two groups but significantly fewer infants had systemic symptoms after the acellular vaccine. Mean log-antibody titres to the agglutinogen and toxin components were higher with the acellular than with the whole-cell vaccine. Persistence of antibodies one year after the third dose was also better in the acellular group.

引用

页码：70 / 73

页数：4

共 11 条

[1]

[Anonymous], 1988, LANCET, Vi, P955

[2]

KURONEN T, 1979, INT S PERTUSSIS, P34

[3] HAEMOPHILUS-INFLUENZAE INFECTIONS AND WHOOPING-COUGH [J].